Tricida, Inc. (TCDA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

tcda · pe ratio · data through Jun 9, 2026

Core PE Ratio Metrics

Trailing 12 months · TTM

Insufficient PE history data (fewer than 3 valid fiscal years).

PE Ratio vs Peers

Biotechnology · 5 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
Tricida, Inc.You TCDA	$6M	N/A	—	—
Aptose Biosciences Inc. APTO	$4M	N/A	—	$0.00
BiondVax Pharmaceuticals Ltd. BVXV	$5M	N/A	—	-$0.20
Entero Therapeutics, Inc. ENTO	$14M	N/A	—	-$4.05
Fresh Tracks Therapeutics, Inc. FRTX	$6M	N/A	—	-$0.96
Gamida Cell Ltd. GMDA	$4M	N/A	—	-$0.42

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Tricida, Inc. (TCDA) measures how much investors pay for each dollar of the company's trailing earnings. TCDA's current PE ratio of N/A is calculated by dividing its stock price of $0.11 by its TTM earnings per share of —.

PE Ratio = Stock Price ÷ EPS (TTM)

= $0.11 ÷ — = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

TCDA pe ratio · 6 questions

TCDA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.11 and TTM EPS of —. Data sourced from Financial Modeling Prep via TCDA's SEC 10-K and 10-Q filings.

TCDA PE ratioWhat is TCDA PE ratioCurrent PE ratio of TCDATCDA PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Tricida, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09